Results 11 to 20 of about 18,010 (199)

National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa [PDF]

Antibiotics
Background: Meropenem–vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an ...
Aurélien Dinh, Alexandre Bleibtreu, Clara Duran, Frédérique Bouchand, Alexie Bosch, Jullien Crozon-Clauzel, Mariam Roncato-Saberan, Morgan Matt, André Boibieux, Annlyse Fanton, Heidi Wille, Elise Fiaux, Benoît Pilmis, Marie Lacoste, Quentin Saint-Genis, Caroline Thumerelle, Patricia Pavese, Fanny Vuotto, Eric Senneville, Anaïs Potron, Stéphane Corvec, David Boutoille, Katy Jeannot, Laurent Dortet, on behalf of the Meropenem-Vaborbactam French Study Group   +24 more
doaj   +3 more sources

Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales. [PDF]

J Antimicrob Chemother, 2023
Abstract Background The treatment options for infections caused by carbapenem-resistant Enterobacterales (CRE) are extremely scarce nowadays and the development of new antibiotics does not follow the exponential increase in the dissemination of carbapenem resistance determinants worldwide.
Nordmann P, Kerbol A, Bouvier M, Sadek M, Poirel L, Raro OHF.   +5 more
europepmc   +6 more sources

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae

Infection and Drug Resistance, 2018
Lindsay A Petty,1 Oryan Henig,1 Twisha S Patel,2 Jason M Pogue,3 Keith S Kaye1 1Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA; 2Department of Pharmacy Services, University of ...
Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS   +4 more
doaj   +5 more sources

Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination [PDF]

Expert Review of Anti-Infective Therapy, 2020
infections due to carbapenem-resistant Enterobacterales (CRE) constitute a worldwide threat and are associated with significant mortality, especially in fragile patients, and costs. Meropenem-vaborbactam (M/V) is a combination of a group 2 carbapenem with a novel cyclic boronic acid-based β-lactamase inhibitor which has shown good efficacy against KPC ...
Andrea Novelli, Gian Maria Rossolini, Mario Tumbarello   +2 more
exaly   +6 more sources

Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018 [PDF]

Antibiotics, 2021
Meropenem/Vaborbactam (MEM-VAB) is a novel carbapenem- β-lactamase inhibitor active against KPC-producing Enterobacteria. Herein, we evaluate the incidence of meropenem/vaborbactam-resistance among KPC-producing K.
Paolo Gaibani, Donatella Lombardo, Linda Bussini, Federica Bovo, Beatrice Munari, Maddalena Giannella, Michele Bartoletti, Pierluigi Viale, Tiziana Lazzarotto, Simone Ambretti   +9 more
doaj   +3 more sources

Potency of Meropenem-Vaborbactam in Lung Surfactant [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT This study investigated whether pulmonary surfactant has an effect on the in vitro antibacterial activity of either meropenem alone or meropenem in combination with vaborbactam at a fixed concentration of 8 μg/ml against several Klebsiella pneumoniae carbapenemase (KPC ...
Debora, Rubio-Aparicio, Jeff, Loutit, Michael, Dudley, Olga, Lomovskaya   +3 more
openaire   +3 more sources

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections [PDF]

Journal of Clinical Medicine, 2019
This study reports the integrated analysis of two phase III studies of meropenem-vaborbactam in the treatment of acute bacterial infections. Targeting Antibiotic Non-Susceptible Gram-Negative Organisms (TANGO) I compared the clinical efficacy and tolerability of meropenem-vaborbactam and piperacillin-tazobactam in the treatment of complicated urinary ...
Chih-Cheng Lai, Chi-Chung Chen, Hung-Jen Tang   +2 more
openaire   +4 more sources

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales

Antibiotics, 2023
Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’
Rémy A. Bonnin, Sandrine Bernabeu, Cécile Emeraud, Thierry Naas, Delphine Girlich, Agnès B. Jousset, Laurent Dortet   +6 more
doaj   +2 more sources

Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam. [PDF]

BMC Genom Data
Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +7 more sources

Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant Enterobacteriaceae

Expert Review of Anti-infective Therapy, 2022
The review aims to review the positioning of meropenem-vaborbactam in clinical practice, taking into consideration the characteristics of other available drugs, namely ceftazidime-avibactam, plazomicin, and colistin. The search terms ‘meropenem-vaborbactam’ or RX7009 for the years 2006 until 2021 were used.
Mouktaroudi, M., Kotsaki, A., Giamarellos-Bourboulis, E.J.   +2 more
openaire   +4 more sources